BHVN - Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday? | Benzinga
Wednesday, Altimmune Inc (NASDAQ:ALT) said the body composition study of pemvidutide showed lean mass preservation, with 25.5% of weight loss derived from lean mass with 74.5% of weight loss from adipose tissue, comparable to the effects historically associated with diet and exercise.
Altimmune will present the complete data analysis at an upcoming scientific meeting.
In December 2023, Altimmune announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide with 391 subjects.
At Week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% at the 1.2 mg, 1.8 mg, ...